Close Cookie Popup
Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Angiogenesis Analytics
Detecting, locating, and characterizing prostate cancer using ultrasound

Angiogenesis Analytics, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. Angiogenesis Analytics eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, Angiogenesis Analytics addresses a significant global need for better prostate cancer diagnostics.

Active
🇳🇱 Netherlands
Angiogenesis Analytics
Nilocas
A cardiac device for the detection of coronary artery disease

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Active
🇬🇧 United Kingdom
Nilocas
Venous Stent
World's first in length adjustable multi-segmented venous stent

The Venous Stent is a new type of stent designed to help with conditions like deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). Unlike older stents, this one can adjust in length and has multiple parts, making it more flexible and better for the veins. It helps improve blood flow and healing in the veins, potentially reducing the need for long-term medication.

Active
🇳🇱 Netherlands
Venous Stent
Superseton
Smooth, simple, secure knotless seton solution for fistula drainage

Superseton is a special device used to help drain fistulas near the anus. Unlike the usual methods that can be painful, Superseton is smooth and doesn't need any knots, making it more comfortable for patients. It's easy for doctors to use and doesn't take long to apply. This makes it a better option for patients with conditions like Crohn’s disease, and it fits well with how doctors already work.

Active
🇳🇱 Netherlands
Superseton
Aspect Neuroprofiles
Machine-learning to improve diagnosis and management of autism

Aspect Neuroprofiles is tackling the challenges of diagnosing and treating Autism Spectrum Disorder (ASD) by combining EEG technology with Artificial Intelligence. Their method objectively measures brain activity related to ASD, improving diagnosis accuracy and predicting treatment effectiveness. This approach aims to shift from subjective assessments to objective physiological measurements, offering hope for millions affected by ASD and mental health issues.

Active
🇳🇱 Netherlands
Aspect Neuroprofiles
Porous Gmbh
Assessing cortical bone health with ultrasound

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Active
🇩🇪 Germany
Porous Gmbh
Foveo
Enhancing assisted fertility through optimal environment control

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

Active
🇬🇧 United Kingdom
Foveo
Loresa
Improving access to laparoscopy in low-resource settings

Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.

Active
🇳🇱 Netherlands
Loresa

Our impact

14
Countries active in
20-25
Ventures built annually
247K
Patients impacted
70+
Active ventures in our portfolio
80+
Healthcare experts
€135M+
Raised by NLC ventures

Explore our 2023 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Nina Rijnders
Investor Relations